The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections in less than 5 hours.
For Research Use Only. Not for use in diagnostic procedures.
Unyvero Urinary Tract Infection (UTI) Panel*
*Unyvero UTI panel is not cleared with the U.S. Food and Drug Administration (FDA). The Unyvero UTI Panel is for Research Use only. Not for use in diagnostic procedures.
Fast and Simple Syndromic Testing with Sample-to-Answer Unyvero System
- Rapid detection – sample to result in under 5 hours
- Direct from native specimen – midstream, suprapubic and fresh catheter urines
- PCR technology – multiplex, broad spectrum of clinically relevant pathogens and antibiotic resistance markers associated with UTIs
- Cartridge-based – simple, easy to use
- Random access – scalable configuration
Urinary tract infections (UTIs) are a common health problem and among the most prevalent infectious diseases in both outpatient and inpatient settings. Complicated UTIs (cUTIs) are a leading cause of hospital admission and associated with higher morbidity and mortality.
Urinary tract infections, including cUTIs, result in a considerable economic and public health burden, frequently and substantially affecting patients’ quality of life. In the U.S., UTIs result annually in an estimated 7 million physician office visits, 1 million visits to Emergency Departments, and over 100,000 hospitalizations, with an overall associated total healthcare cost of $2 billion. During the past two decades, UTIs have contributed to a significant increase in hospitalizations in the U.S.1
Urinary tract infections (UTIs) are a common health problem in both outpatient and inpatient settings:
- UTIs account for more than 100,000 hospital admissions annually1
- 30-44% of women will have a UTI recurrence within 6 months of initial infection2
- Left untreated, chronic UTIs cause ongoing, debilitating and life-changing symptoms3
- Complicated UTIs can lead to treatment failure and significant morbidity and mortality4
- UTIs are increasingly caused by multidrug-resistant organisms as a result of the overuse of empirical, broad-spectrum antibiotic therapy5
The emergence of multidrug-resistant pathogens — recognized as a healthcare threat of global proportions — is driving the need for rapid diagnosis and prudent use of antibiotics.
UTIs are frequently treated empirically. Antibiotic overuse leads to antibiotic resistance. Consequently, the number of urinary tract infections caused by antibiotic-resistant bacteria is increasing.5 Considering the global increase in antimicrobial resistance (AMR), accurate and timely diagnosis of UTIs is important.
The slow turn-around-time of current laboratory methods may lead to delays in appropriate antimicrobial therapy, potentially contributing to patient harm and to rising costs of healthcare and excessive use of broad-spectrum antibiotics.
As with other serious infections, the key for effective treatment is the early diagnosis of pathogens and associated resistance markers. This allows targeted treatment, better use of available antibiotics, decreased length of hospital stays, and lower healthcare costs.
The Unyvero UTI panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections in less than 5 hours.
- J. E. Simmering, et al. The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011. Open Forum Infectious Diseases. 2017.
- J. J. Arnold, et al. Common Questions About Recurrent Urinary Tract Infections in Women. American Academy of Family Physicians 2016 www.aafp.org/afp.
- Chronic Urinary Tract Infection Campaign 2018 https://www.cutic.co.uk/what-is-chronic-uti/.
- A. Sabih et al. Complicated Urinary Tract Infections, updated July 17, 2020 ID: NBK436013PMID: 28613784.
- R. Paul, State of the Globe: Rising Antimicrobial Resistance of Pathogens in Urinary Tract Infections. J Glob Infect Dis. 2018 doi:10.4103/jgid.jgid_104_17.